Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial by Gettinger, Scott N, Dr, Bazhenova, Lyudmila A, Prof, Langer, Corey J, Prof, Salgia, Ravi, Prof, Gold, Kathryn A, MD, Rosell, Rafael, Prof, Shaw, Alice T, MD, Weiss, Glen J, MD, Tugnait, Meera, PhD, Narasimhan, Narayana I, PhD, Dorer, David J, PhD, Kerstein, David, MD, Rivera, Victor M, PhD, Clackson, Timothy, PhD, Haluska, Frank G, MD, Camidge, David Ross, Prof

Get full text